How I manage cold agglutinin disease

British Journal of Haematology

Volumn 153, Issue 3, 2011, Pages 309-317

  Berentsen, Sigbjørn ^a  

^a HAUGESUND HOSPITAL   (Norway)

Author keywords

Autoimmune haemolytic anaemia; Cold agglutinin disease; Fludarabine; Lymphoproliferative; Rituximab

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; AZATHIOPRINE; CLADRIBINE; COLD AGGLUTININ; CORTICOSTEROID; ERYTHROPOIETIN; FLUDARABINE; RITUXIMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BLOOD TOXICITY; CLINICAL TRIAL (TOPIC); CLONAL VARIATION; COLD AGGLUTININ SYNDROME; COMBINATION CHEMOTHERAPY; COMPLEMENT SYSTEM; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVASCULAR HEMOLYSIS; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NEUTROPENIA; PATIENT COUNSELING; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTECTIVE CLOTHING; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPLENECTOMY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; VIDARABINE;

EID: 79953869932     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08643.x     Document Type: Review

References (78)

1. Bartholomew, J.R., Bell, W.R. & Shirey, R.S. (1987) Cold agglutinin hemolytic anemia: management with an environmental suit. Annals of Internal Medicine, 106, 243-244.
2. Berentsen, S. (1995) [Chronic cold agglutinin disease]. Tidsskrift for Den Norske Laegeforening, 115, 473-475. (In Norwegian).
3. Berentsen, S. (2007) Rituximab for the treatment of autoimmune cytopenias. Haematologica, 92, 1589-1596.
4. Berentsen, S. (2009) Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom's macroglobulinemia. Clinical Lymphoma & Myeloma, 9, 110-112.
5. Berentsen, S., Bo, K., Shammas, F.V., Myking, A.O. & Ulvestad, E. (1997) Chronic cold agglutinin disease of the 'idiopathic' type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS, 105, 354-362.
6. Berentsen, S., Tjonnfjord, G.E., Shammas, F.V., Bergheim, J., Hammerstrom, J., Langholm, R. & Ulvestad, E. (2000) No response to cladribine in five patients with chronic cold agglutinin disease. European Journal of Haematology, 65, 88-90.
7. Berentsen, S., Tjonnfjord, G.E., Brudevold, R., Gjertsen, B.T., Langholm, R., Lokkevik, E., Sorbo, J.H. & Ulvestad, E. (2001) Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. British Journal of Haematology, 115, 79-83.
8. Berentsen, S., Ulvestad, E., Gjertsen, B.T., Hjorth-Hansen, H., Langholm, R., Knutsen, H., Ghanima, W., Shammas, F.V. & Tjonnfjord, G.E. (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood, 103, 2925-2928.
9. Berentsen, S., Ulvestad, E., Langholm, R., Beiske, K., Hjorth-Hansen, H., Ghanima, W., Sorbo, J.H. & Tjonnfjord, G.E. (2006) Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica, 91, 460-466.
10. Berentsen, S., Beiske, K. & Tjonnfjord, G.E. (2007a) Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology, 12, 361-370.
11. Berentsen, S., Ulvestad, E. & Tjonnfjord, G.E. (2007b) B-lymphocytes as targets for therapy in chronic cold agglutinin disease. Cardiovascular & Haematological Disorders Drug Targets, 7, 219-227.
12. Berentsen, S., Randen, U., Vagan, A.M., Hjorth-Hansen, H., Vik, A., Dalgaard, J., Jacobsen, E.M., Thoresen, A.S., Beiske, K. & Tjonnfjord, G.E. (2010) High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood, 116, 3180-3184.
13. Beutler, E., Sipe, J., Romine, J., McMillan, R., Zyroff, J. & Koziol, J. (1996) Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Seminars in Hematology, 33, 45-52.
14. Camou, F., Viallard, J.F. & Pellegrin, J.L. (2003) [Rituximab in cold agglutinin disease]. La Revue de médecine interne, 24, 501-504. (In French).
15. Carson, K.R., Beckwith, L.G. & Mehta, J. (2010) Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood, 115, 915.
16. Cesana, C., Barbarano, L., Miqueleiz, S., Lucchesini, C., Ricci, F., Varettoni, M., Filippini, D., Lazzarino, M. & Morra, E. (2005) Clinical characteristics and outcome of immunoglobulin M related disorders. Clinical Lymphoma, 5, 261-264.
17. Christenson, W.N., Dacie, J.V., Croucher, B.E. & Charlwood, P.A. (1957) Electrophoretic studies on sera containing high-titre cold haemagglutinins: identification of the antibody as the cause of an abnormal gamma 1 peak. British Journal of Haematology, 3, 262-275.
18. Cohen, Y., Polliack, A., Zelig, O. & Goldfarb, A. (2001) Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma. Leukemia & Lymphoma, 42, 1405-1408.
19. Cooper, N. & Arnold, D.M. (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. British Journal of Haematology, 149, 3-13.
20. Czuczman, M.S., Koryzna, A., Mohr, A., Stewart, C., Donohue, K., Blumenson, L., Bernstein, Z.P., McCarthy, P., Alam, A., Hernandez-Ilizaliturri, F., Skipper, M., Brown, K., Chanan-Khan, A., Klippenstein, D., Loud, P., Rock, M.K., Benyunes, M., Grillo-Lopez, A. & Bernstein, S.H. (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. Journal of Clinical Oncology, 23, 694-704.
21. Dacie, J. (1992a) The auto-immune haemolytic anaemias: introduction. In: The Haemolytic Anaemias, Vol. 3 (ed. by J. Dacie), pp. 1-5. Churchill Livingstone, London.
22. Dacie, J. (1992b) Treatment and prognosis of cold-antibody AIHA. In: The Haemolytic Anaemias, Vol. 3 (ed. by J. Dacie), pp. 502-508. Churchill Livingstone, London.
23. Dacie, J. (1992c) Auto-immune haemolytic anaemia (AIHA): cold antibody syndromes I: idiopathic types: clinical presentation and haematological and serological findings. In: The Haemolytic Anaemias, Vol. 3 (ed. by J. Dacie), pp. 210-239. Churchill Livingstone, London.
24. Dacie, J. (1992d) Auto-immune haemolytic anaemia (AIHA): cold-antibody syndromes II: immunochemistry and specificity of the antibodies; serum complement in auto-immune haemolytic anaemia. In: The Haemolytic Anaemias, Vol. 3 (ed. by J. Dacie), pp. 240-295. Churchill Livingstone, London.
25. Engelhardt, M., Jakob, A., Ruter, B., Trepel, M., Hirsch, F. & Lubbert, M. (2002) Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood, 100, 1922-1923.
26. Fest, T., de Wazieres, B., Lamy, B., Maskani, M., Vuitton, D. & Dupond, J.L. (1994) Successful response to alpha-interferon 2b in a refractory IgM autoagglutinin-mediated hemolytic anemia. Annals of Hematology, 69, 147-149.
27. Finazzi, G. (2002) Rituximab in autoimmune cytopenias: for which patients? Haematologica, 87, 113-114.
28. Genty, I., Michel, M., Hermine, O., Schaeffer, A., Godeau, B. & Rochant, H. (2002) [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases]. La Revue de médecine interne, 23, 901-909. (In French).
29. Gertz, M.A. (2006) Cold agglutinin disease. Haematologica, 91, 439-441.
30. Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. & Cerny, T. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule. Blood, 103, 4416-4423.
31. Harboe, M. & Deverill, J. (1964) Immunochemical properties of cold haemagglutinins. Scandinavian Journal of Haematology, 61, 223-237.
32. Harboe, M., van Furth, R., Schubothe, H., Lind, K. & Evans, R.S. (1965) Exclusive occurrence of K chains in isolated cold haemagglutinins. Scandinavian Journal of Haematology, 2, 259-266.
33. Harjunpaa, A., Junnikkala, S. & Meri, S. (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology, 51, 634-641.
34. Hillen, H.F. & Bakker, S.J. (1994) Failure of interferon-alpha-2b therapy in chronic cold agglutinin disease. European Journal of Haematology, 53, 242-243.
35. Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socie, G., Muus, P., Roth, A., Szer, J., Elebute, M.O., Nakamura, R., Browne, P., Risitano, A.M., Hill, A., Schrezenmeier, H., Fu, C.L., Maciejewski, J., Rollins, S.A., Mojcik, C.F., Rother, R.P. & Luzzatto, L. (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 355, 1233-1243.
36. Hippe, E., Jensen, K.B., Olesen, H., Lind, K. & Thomsen, P.E. (1970) Chlorambucil treatment of patients with cold agglutinin syndrome. Blood, 35, 68-72.
37. Jacobs, A. (1996) Cold agglutinin hemolysis responding to fludarabine therapy. American Journal of Hematology, 53, 279-280.
38. Jaffe, C.J., Atkinson, J.P. & Frank, M.M. (1976) The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. Journal of Clinical Investigation, 58, 942-949.
39. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (eds). (2001) Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Vol. 3. IARC Press, Lyon.
40. Jonsen, J., Kass, E. & Harboe, M. (1961) Complement and complement components in acquired hemolytic anemia with high titer cold antibodies. Acta Medica Scandinavica, 170, 725-729.
41. Kirschfink, M., Knoblauch, K. & Roelcke, D. (1994) Activation of complement by cold agglutinins. Infusionstherapie und Transfusionsmedizin, 21, 405-409.
42. Landsteiner, K. (1903) [Über Beziehungen zwischen dem Blutserum und den Körperzellen]. Münchenen medizinische Wochenschrift, 50, 1812-1814. (In German).
43. Layios, N., Van Den, N.E., Jost, E., Deneys, V., Scheiff, J.M. & Ferrant, A. (2001) Remission of severe cold agglutinin disease after rituximab therapy. Leukemia, 15, 187-188.
44. Lee, E.J. & Kueck, B. (1998) Rituxan in the treatment of cold agglutinin disease. Blood, 92, 3490-3491.
45. Leleu, X., Tamburini, J., Roccaro, A., Morel, P., Soumerai, J., Levy, V., Wemeau, M., Balkaran, S., Poulain, S., Hunter, Z.R., Ghobrial, I.M., Treon, S.P. & Leblond, V. (2009) Balancing risk versus benefit in the treatment of Waldenstrom's macroglobulinemia patients with nucleoside analogue-based therapy. Clinical Lymphoma & Myeloma, 9, 71-73.
46. Lyckholm, L.J. & Edmond, M.B. (1996) Images in clinical medicine. Seasonal hemolysis due to cold-agglutinin syndrome. New England Journal of Medicine, 334, 437.
47. Mease, P.J. (2008) B-cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. Journal of Rheumatology, 35, 1245-1255.
48. Ness, P.M., Bell, W.R. & Shirey, R.S. (2003) Transfusion medicine illustrated. Novel management of cold agglutinin disease. Transfusion, 43, 839.
49. Nydegger, U.E., Kazatchkine, M.D. & Miescher, P.A. (1991) Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Seminars in Hematology, 28, 66-77.
50. O'Connor, B.M., Clifford, J.S., Lawrence, W.D. & Logue, G.L. (1989) Alpha-interferon for severe cold agglutinin disease. Annals of Internal Medicine, 111, 255-256.
51. Oluboyede, O.A., Bademosi, O., David-West, A., Thomas, C.O., Francis, T.I. & Luzzatto, L. (1976) Monoclonal gammopathy (Waldenstrom's macroglobulinaemia) producing specific red cell antibody. Journal of Clinical Pathology, 29, 219-223.
52. Owen, R.G., Treon, S.P., Al Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. & Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Seminars in Oncology, 30, 110-115.
53. Pascual, V., Victor, K., Spellerberg, M., Hamblin, T.J., Stevenson, F.K. & Capra, J.D. (1992) VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. Journal of Immunology, 149, 2337-2344.
54. Provan, D., Butler, T., Evangelista, M.L., Amadori, S., Newland, A.C. & Stasi, R. (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica, 92, 1695-1698.
55. Rordorf, R., Barth, A., Nydegger, U. & Tobler, A. (1994) Treatment of severe idiopathic cold-agglutinin diseases using interferon-alpha 2b. Schweizerische medizinische Wochenschrift, 124, 56-61. (In German).
56. Rosenfield, R.E. & Jagathambal (1976) Transfusion therapy for autoimmune hemolytic anemia. Seminars in Hematology, 13, 311-321.
57. Rosse, W.F. & Adams, J.P. (1980) The variability of hemolysis in the cold agglutinin syndrome. Blood, 56, 409-416.
58. Roth, A., Huttmann, A., Rother, R.P., Duhrsen, U. & Philipp, T. (2009) Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood, 113, 3885-3886.
59. Schollkopf, C., Kjeldsen, L., Bjerrum, O.W., Mourits-Andersen, H.T., Nielsen, J.L., Christensen, B.E., Jensen, B.A., Pedersen, B.B., Taaning, E.B., Klausen, T.W. & Birgens, H. (2006) Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leukemia & Lymphoma, 47, 253-260.
60. Schreiber, A.D., Herskovitz, B.S. & Goldwein, M. (1977) Low-titer cold-hemagglutinin disease. Mechanism of hemolysis and response to corticosteroids. New England Journal of Medicine, 296, 1490-1494.
61. Schubothe, H. (1966) The cold hemagglutinin disease. Seminars in Hematology, 3, 27-47.
62. Silberstein, L.E., Berkman, E.M. & Schreiber, A.D. (1987) Cold hemagglutinin disease associated with IgG cold-reactive antibody. Annals of Internal Medicine, 106, 238-242.
63. Silverman, G.J. (2007) Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Frontiers of Bioscience, 12, 2194-2206.
64. Sokol, R.J., Hewitt, S. & Stamps, B.K. (1981) Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. British Medical Journal (Clinical Research Edition), 282, 2023-2027.
65. Stone, M.J. (2010) Heating up cold agglutinins. Blood, 116, 3119-3120.
66. Taylor, R.P. & Lindorfer, M.A. (2007) Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nature Clinical Practice. Rheumatology, 3, 86-95.
67. Taylor, R.P. & Lindorfer, M.A. (2008) Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Current Opinion in Immunology, 20, 444-449.
68. Thorpe, S.J., Boult, C.E., Stevenson, F.K., Scott, M.L., Sutherland, J., Spellerberg, M.B., Natvig, J.B. & Thompson, K.M. (1997) Cold agglutinin activity is common among human monoclonal IgM Rh system antibodies using the V4-34 heavy chain variable gene segment. Transfusion, 37, 1111-1116.
69. Treon, S.P. (2009) How I treat Waldenstrom macroglobulinemia. Blood, 114, 2375-2385.
70. Treon, S.P., Loakimidis, L., Soumerai, J.D., Patterson, C.J., Hunter, Z.R., Feiner, A., Mattern, J., Birner, A., Boral, A. & Ghobrial, I.M. (2008) Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of the WMCTG clinical trial 05-180. ASCO annual meeting 2008. Journal of Clinical Oncology, 26, Abstract 8519.
71. Treon, S.P., Branagan, A.R., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Turnbull, B., Wasi, P., Emmanouilides, C., Frankel, S.R., Lister, A., Morel, P., Matous, J., Gregory, S.A. & Kimby, E. (2009) Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood, 113, 3673-3678.
72. Ulvestad, E. (1998) Paradoxical haemolysis in a patient with cold agglutinin disease. European Journal of Haematology, 60, 93-100.
73. Ulvestad, E., Berentsen, S., Bo, K. & Shammas, F.V. (1999) Clinical immunology of chronic cold agglutinin disease. European Journal of Haematology, 63, 259-266.
74. Ulvestad, E., Berentsen, S. & Mollnes, T.E. (2001) Acute phase haemolysis in chronic cold agglutinin disease. Scandinavian Journal of Immunology, 54, 239-242.
75. Wiener, A.S., Unger, L.J., Cohen, L. & Feldman, J. (1956) Type-specific cold auto-antibodies as a cause of acquired hemolytic anemia and hemolytic transfusion reactions: biologic test with bovine red cells. Annals of Internal Medicine, 44, 221-240.
76. Worlledge, S.M., Brain, M.C., Cooper, A.C., Hobbs, J.R. & Dacie, J. (1968) Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia. Proceedings of the Royal Society of Medicine, 61, 1312-1315.
77. Zilow, G., Kirschfink, M. & Roelcke, D. (1994) Red cell destruction in cold agglutinin disease. Infusionstherapie und Transfusionsmedizin, 21, 410-415.
78. Zoppi, M., Oppliger, R., Althaus, U. & Nydegger, U. (1993) Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionstherapie und Transfusionsmedizin, 20, 19-22.